India’s pharmaceutical industry has received a significant tariff reprieve from the United States, with Washington deciding to impose a zero per cent tariff on a range of speciality medicines and associated ingredients used for rare and critical medical conditions. The exemption comes as the US prepares to introduce a 100 per cent tariff on certain patented pharmaceutical imports, marking an important distinction between medicines considered strategically sensitive and those essential for treating specialised medical conditions.
The US Commerce Department has published a list of jurisdictions whose qualifying pharmaceutical products will receive the zero per cent tariff treatment. India is among 20 jurisdictions covered by the exemption, which includes medicines and ingredients linked to rare-disease treatments, infertility care, advanced therapies and certain animal pharmaceuticals.
The decision follows President Donald Trump’s April 2 proclamation seeking to impose tariffs on imports of patented pharmaceuticals, biologics and related ingredients. The measure was framed as part of a broader effort to encourage pharmaceutical manufacturing within the United States and reduce dependence on overseas supply chains.
Under the newly notified arrangements, drugs designated for rare diseases will qualify for a zero per cent tariff when imported from the listed jurisdictions. The exemption also covers medicines used for infertility treatment, cell therapies, gene therapies and antibody-drug conjugates (ADCs). Associated components and ingredients used in these qualifying medicines will similarly receive the zero-tariff treatment.
For India, the decision is particularly relevant because the country is a major supplier of generic medicines and pharmaceutical products to international markets. The exemption for specialised medicines provides a measure of protection for Indian pharmaceutical exporters dealing with highly specialised therapies, while the broader US tariff policy continues to place pressure on other categories of patented pharmaceutical imports.
The other jurisdictions included in the zero-tariff category are Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland, Liechtenstein, Taiwan, Thailand, the United Kingdom and Vietnam.
According to the US Commerce Department notice, qualifying products from these jurisdictions are eligible for the zero per cent rate because the jurisdictions have a current or forthcoming trade and security framework agreement with the United States. The exemption is therefore linked not only to the nature of the medicines but also to the wider economic and strategic arrangements between Washington and the respective jurisdictions.
The move forms part of the implementation of the Trump administration’s April proclamation under Section 232 of the Trade Expansion Act. Section 232 provides the US government with a mechanism to adjust imports when they are considered relevant to national security concerns.
The distinction between the broader tariff regime and the speciality-drug exemptions is significant for pharmaceutical supply chains. While Washington is seeking to encourage greater domestic production of patented medicines and pharmaceutical ingredients, the exemptions recognise the specialised nature of certain therapies and the importance of maintaining access to them.
For Indian pharmaceutical companies, the zero-tariff provision could help preserve access to the US market for qualifying products and their associated ingredients. At the same time, the exemption is specific rather than universal: medicines outside the notified categories remain subject to the wider US tariff framework applicable to pharmaceutical imports.
Leave Your Comment